HealthDay News – According to a study published online Dec. 1 in the Journal of Internal Medicine, direct use of oral anticoagulants (DOAC) is not associated with a reduction in the risk of severe COVID-19.
Benjamin Flam, MD of Karolinska University Medical Center in Stockholm and colleagues looked at whether continued use of DOAC was associated with a reduced risk of hospitalization for laboratory-confirmed COVID-19 in a nationwide registered cohort study in Sweden from February to May 2020.
The researchers did not observe an association for using DOAC with a reduced risk of hospitalization for COVID-19 compared to no use in a comparison group of patients with atrial fibrillation (adjusted hazard ratio, 1.00; 95 percent confidence interval, 0.75 up to 1.33) and in a comparison group of patients with cardiovascular diseases (adjusted hazard ratio, 0.94; 95 percent confidence interval, 0.80 to 1.10). In addition, no association was found between use of DOAC and ICU admission or death due to COVID-19 (adjusted hazard rates: 0.76) [95 percent confidence interval, 0.51 to 1.12] and 0.90 [95 percent confidence interval, 0.71 to 1.15], respectively).
“Our results suggest that early DOAC treatment does not protect against severe COVID-19, but these should be treated with caution as differences between the difficult-to-measure groups may persist,” Flam said in a statement. “Our study also says nothing about whether other types of anticoagulants might be effective, but there are numerous clinical trials being conducted worldwide.”
The study was funded by the Janssen Corporation.
Summary / full text (subscription or payment required)
COVID19 Emerging Diseases General Cardiology Respiratory